Exciting Presentation by Adagene at ASCO Annual Meeting
Adagene Inc. (Nasdaq: ADAG), an innovative biotechnology company, is gearing up for a significant event at the upcoming ASCO 2025 annual meeting. This renowned conference, taking place in Chicago, serves as a platform for professionals in the oncology field to discuss the latest advancements in cancer research and treatments.
Poster Presentation Highlights
Adagene announced that it will showcase a poster titled "Safety and Efficacy of ADG126 (an Anti-CTLA-4 Masking Antibody) in Combination with Pembrolizumab: Updated Results of Phase 1b/2 Study in Advanced MSS CRC." This exciting research will be presented on Saturday, and attendees can engage with the findings during the dedicated poster viewing session from 9:00 AM to 12:00 PM CDT.
Details of the Presentation
The poster will be displayed at Board #248, located within the McCormick Place convention center. This presentation will delve into the evolving landscape of cancer therapies, particularly focusing on the treatment of Metastatic Microsatellite-stable Colorectal Cancer (CRC) using Adagene’s groundbreaking drug ADG126.
About Adagene and Its Innovations
Adagene is leading the charge in antibody-based cancer immunotherapies, utilizing its proprietary Dynamic Precision Library (DPL) technology to create novel therapeutics. The company blends computational biology and artificial intelligence, allowing it to craft antibodies that can precisely target tumor cells while sparing healthy tissues.
The Role of SAFEbody Technology
The company’s SAFEbody technology is particularly exciting as it addresses safety concerns associated with traditional antibody treatments. By employing precision masking technology, SAFEbody shields the drug’s binding domain, permitting it to activate specifically within the tumor microenvironment. This approach minimizes off-tumor toxicity, a significant advancement in the effectiveness and safety of immunotherapy.
Current Clinical Programs
Adagene’s flagship program, ADG126 (muzastotug), is a notable anti-CTLA-4 SAFEbody that directly targets regulatory T cells (Tregs) in tumors. It is currently undergoing phase 1b/2 clinical trials alongside anti-PD-1 therapy, positioning Adagene at the forefront of breakthrough cancer treatments.
While the research focuses on Colorectal Cancer, the adaptable SAFEbody platform shows potential across various therapeutic modalities, including antibody-drug conjugates and multi-specific T-cell engagers, promising a broader application in oncology.
Connecting with the Future
For professionals interested in the latest developments from Adagene, more information can be found on their investor website. This platform not only provides insights into ongoing research but also showcases their collaborations with leading global partners that enhance their innovative approaches.
Adagene is also active on popular social media platforms where updates on their innovations and corporate activities are regularly shared, allowing stakeholders to stay informed about their impactful work in the cancer research landscape.
Frequently Asked Questions
What is the focus of Adagene's upcoming presentation at ASCO?
The focus is on the safety and efficacy of ADG126 in combination with Pembrolizumab for Advanced MSS CRC.
When will Adagene's poster presentation take place?
The poster presentation is scheduled for Saturday during the ASCO 2025 meeting from 9:00 AM to 12:00 PM CDT.
What is SAFEbody technology?
SAFEbody technology is designed to enhance safety by masking the binding domain of antibodies, allowing them to target tumors while limiting off-target toxicity.
Who is attending the presentation?
Researchers, oncologists, and healthcare professionals interested in the latest advancements in cancer therapies will attend the presentation.
Where can I find more information about Adagene?
Additional information can be explored on Adagene's official website and their investor relations platform, which feature updates on their research and collaborations.
